India has become a key distributor of oncology medicines in the last few years. It is still growing, with expectations to reach up to USD 1.49 billion between 2024 and 2028. The government’s ease of approval for new formulations, the country’s widespread facilities, experienced professionals, and evolving regulations all contributed to the significant growth of the oncology market in recent years.
Why India Leads in Oncology Pharma?
Part of the oncology drug manufacturer’s job is to deliver quality medicine as quickly as possible, ensuring the utmost safety and effectiveness. India is a country that has a wealth of resources, providing enough support to manufacturers to introduce new solutions without being stuck in a series of clinical studies or making heavy investments.
- Clinical Trials
No pharma company would like to go through the time, the cost, and the hard work of doing a trial because it is long, expensive, and time-consuming. One of the benefits of India having the capability to do clinical research is the fact that it:
- A diverse patient pool with varied ethnic groups
- A rich genetic pool
- Skilled investigators and infrastructure to help with high-quality data collection and running complex studies
- Favorable regulatory support to increase predictability without stretching the timeline
- A growing oncology pharma market
The wealth of the country is its ever-growing population. Nearly half of these people have limited prior exposure to certain treatments, which offers a unique opportunity to study the efficacy and safety of new interventions without the confounding effects of previous therapies. That’s why progressing from preclinical studies to human trials is much faster here.
- Keep Innovating New Solutions
The demand drives companies to put so many resources into their R&D. Typically, millions of cases are diagnosed yearly. The surge in numbers comes from various reasons, as people nowadays are more attached to technology and alterations in healthy diets. The largest oncology pharmaceutical companies in India are putting their effort into these drastic changes, focusing on what drives the increased diagnosis and offering corresponding solutions — we’re talking about 1.4 billion people.
If you look at Pinnacle, a leading oncology medicine manufacturer, its oncology portfolio has diverse variations. To treat varying diseases, pharma companies in India make medicines that are more targeted and based on immune power.
Our developmental approaches are strategic and layered. They are designed to address different stages of cancer progression across various age groups. Leveraging our R&D capabilities, we deliver advanced oncology treatments in several ways:
- Stimulating immune responses
- Repairing DNA mechanisms
- Combining antibodies with specific cancer cells while sparing healthy tissues
- Targeting genetic mutations that resist existing therapies
- Modifying patients’ own immune cells for personalised treatment
Companies are stretching affordability. Anticancer medicines are some of the costliest medicines of all, especially when they are patented and supplied under brand names. By 2021, India distributed more than 1,351 generic oncology drugs, with the highest focus on blood cancer and leukaemia. Increasing the generic version of complex drugs and making them affordable is what sets India apart as a leading oncology medicine producer.
- Collaboration and Partnership with Leading Firms
Collaboration between two organisations is prevalent. Major industries like Cipla and Biocon have taken advantage of their alliance to expand their access and explore biosimilarity. This also offers companies the opportunity to enter new markets and develop new therapies.
By collaborating with various stakeholders, such as foreign governments and healthcare institutions, Indian firms gain value in their procurement processes and increase the availability of essential oncology medications.
- Fast Track Options for Drug Approval
Repeated trials take longer for a new drug to reach the market. Also, this might indicate that patients in the rural parts of the country find it difficult to access medicines. To overcome this delay in bringing effective treatment, the government has issued an order that approved drugs for international regulators can be locally tested. This is only applicable to drugs that have shown their safety and efficacy elsewhere.
The review framework has also been reduced to 30 days for drugs manufactured in India. For foreign-developed medicines, it’s shortened to 90 days to control the rising cancer threats and to provide worthy treatments to every part of the country.
This does not imply that patient safety has not received adequate consideration. The medications must nevertheless adhere to the Central Drugs Standard Control Organization (CDSCO) even when their approval is waived. The post-marketing phase is when the review will take place.
Top Oncology Pharmaceutical Company lists
- Pinnacle Life Science
Pinnacle Life Science, a Mumbai-based subsidiary of Aarti Drugs Ltd., offers a wide range of cancer medications. The firm also provides full oncology CDMO services to healthcare facilities, which include end-to-end support from cancer medication formulation to manufacturing.
- Product portfolio: Pinnacle’s Cancer section offers different products such as Enzalutamide, Capecitabine, and Ruxolitinib.
- R&D: Pinnacle makes many drug forms, like solid and liquid pills, skin treatments, and slow-release medicines.
- Collaborations and partnerships: It collaborates with over 250 clients worldwide. The company allows for co-developments to reach diverse markets.
- Regulatory compliance: Provides ANDAs and NDAs for compliance with local and international standards. Pinnacle conducts detailed patent evaluations for APIs and formulations to ensure product protection.
- Sun Pharma
Sun Pharma is a key pharmaceutical company in India, providing drugs for many areas of treatment, such as generic drugs and medications for special needs.
- Product portfolio: Sun Pharma creates and provides a broad range of iterations and active pharmaceutical ingredients (APIs) in formulations.
- Global presence: The company operates in over 100 countries and has manufacturing plants in the Americas, Europe, and Asia Pacific areas.
- R&D: The company is also involved in developing deuterated pharmaceuticals aimed at creating safer alternatives to existing drugs.
- Advancements: INFUGEM™ is the latest drug delivery method developed by Sun Pharma, which was developed to improve cancer therapy targeting and delivery through the use of new drug delivery systems and nanoparticulate systems, among others.
- Dr Reddy’s Laboratories
Dr Reddy’s Laboratories is a leading API manufacturer and a focused partner for generic formulations. As a result, their list of treatment options includes gastrointestinal problems, cancer, cardiovascular disease, and central nervous system disorders.
Product portfolio: A wide variety of products in the product range consisting of 190+ drugs, 60 APIs, diagnostic kits, and biotechnology products.
Global presence: Operates in over 25 countries.
R&D: Formulates and develops biosimilars to address unmet needs
- Cipla
Cipla is a multi-therapy pharmaceutical company with a significant presence in antiretroviral, cancer, and respiratory treatments. Like Sun Pharma, Cipla is well-known in the US and has a wide range of products that are available worldwide.
- Important products: Cipla offers a range of treatments in its product line. The firm sells a variety of goods, including vaccines, OTC medications, APIs, and both branded and generic medications.
- Global presence: It sells its goods in more than 86 countries and runs 47 production facilities worldwide.
- R&D: Investing in new formulations, drug delivery systems, and APIs. Collaborating with enterprises on know-how transfer, quality control, and expanding its product offerings.
- Digital initiatives: It launched CiplaMed 2.0 (a knowledge-sharing platform offering accurate updates across specialities for healthcare professionals).
- Natco Pharma
Natco Pharma, a Hyderabad-based cancer medicine manufacturer, focuses on manufacturing low-cost generic versions of complicated compounds, particularly in oncology and hepatology.
- Product Portfolio: Natco’s oncology division addresses both haematological cancers and solid tumours.
- R&D: The company specialises in analytical R&D divisions to form parenteral and solid-dose dosage forms. It focuses on new drugs to target mutated forms of cancers.
- Collaboration & Partnership: Natco collaborates with institutions and specialty synthetic and analytical services. The company forms alliances with pharma companies to co-develop and commercialise complex generic and proprietary medicines.
India’s Oncology Drug Manufacturers Provide Affordable and Accessible Solutions
The demand for effective tailor-made cancer medicine in India is higher than elsewhere globally. More than a million cases are diagnosed every single year, each coming with its difficulties that require drastic changes in treatment. Top oncology pharmaceutical company in India is putting their efforts into offering various types of anticancer medicines that are affordable to everyone. Pinnacle Life Science is right here for companies looking for an oncology CDMO specialist who can opt for individual drug formulation and production.
